Leukemia - Table of Contents alert Volume 26 Issue 10

TABLE OF CONTENTS Volume 26, Issue 10 (October 2012) In this issue Special Report from the Euroclonality Consortium: Guidelines for Improved Clonality Diagnostics Reviews Original Articles Letters to the Editor Corrigenda Also new AOP Advertisement BD Reagents for Blood Cell Disorders Part of the building blocks to support patient care for blood cell disorders, BD Biosciences reagents provide a full spectrum of color choices, allowing you to analyze multiple parameters simultaneously and access a whole new world of information and insight. Welcome to a more colorful worldsm. bdbiosciences.com/go/color Sign up for e-alerts Recommend to your library Web feed Subscribe   Advertisement Nature Communications #4 in multidisciplinary sciences with first Impact Factor Nature Communications has joined Nature at the top of the multidisciplinary sciences category with its first impact factor of 7.396* Launched in April 2010, Nature Communications is a multidisciplinary online journal publishing high quality research across all areas of the natural sciences. *2011 Journal Citation Reports® (Thomson Reuters, 2012)   Special Report from the Euroclonality Consortium: Guidelines for Improved Clonality Diagnostics Top EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations A W Langerak, P J T A Groenen, M Brüggemann, K Beldjord, C Bellan, L Bonello, E Boone, G I Carter, M Catherwood, F Davi, M-H Delfau-Larue, T Diss, P A S Evans, P Gameiro, R Garcia Sanz, D Gonzalez, D Grand, Å Håkansson, M Hummel, H Liu, L Lombardia, E A Macintyre, B J Milner, S Montes-Moreno, E Schuuring, M Spaargaren, E Hodges and J J M van Dongen Leukemia 2012 26: 2159-2171; advance online publication, August 24, 2012; 10.1038/leu.2012.246 Abstract | Full Text Reviews Top Standardized definitions of molecular response in chronic myeloid leukemia N C P Cross, H E White, M C Müller, G Saglio and A Hochhaus Leukemia 2012 26: 2172-2175; advance online publication, April 16, 2012; 10.1038/leu.2012.104 Abstract | Full Text Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia R Swords, C Freeman and F Giles Leukemia 2012 26: 2176-2185; advance online publication, April 27, 2012; 10.1038/leu.2012.114 Abstract | Full Text Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia S Anguille, V F Van Tendeloo and Z N Berneman Leukemia 2012 26: 2186-2196; advance online publication, June 1, 2012; 10.1038/leu.2012.145 Abstract | Full Text Original Articles Top THERAPY Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up R A Larson, A Hochhaus, T P Hughes, R E Clark, G Etienne, D-W Kim, I W Flinn, M Kurokawa, B Moiraghi, R Yu, R E Blakesley, N J Gallagher, G Saglio and H M Kantarjian Leukemia 2012 26: 2197-2203; advance online publication, May 18, 2012; 10.1038/leu.2012.134 Abstract | Full Text ACUTE LEUKEMIAS Outcome in children with Down's syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations T D Buitenkamp, R Pieters, N E Gallimore, A van der Veer, J P P Meijerink, H B Beverloo, M Zimmermann, V de Haas, S M Richards, A J Vora, C D Mitchell, L J Russell, C Schwab, C J Harrison, A V Moorman, M M van den Heuvel-Eibrink, M L den Boer and C M Zwaan Leukemia 2012 26: 2204-2211; advance online publication, March 22, 2012; 10.1038/leu.2012.84 Abstract | Full Text Common genetic variation contributes significantly to the risk of childhood B-cell precursor acute lymphoblastic leukemia V Enciso-Mora, F J Hosking, E Sheridan, S E Kinsey, T Lightfoot, E Roman, J A E Irving, I P M Tomlinson, J M Allan, M Taylor, M Greaves and R S Houlston Leukemia 2012 26: 2212-2215; advance online publication, March 29, 2012; 10.1038/leu.2012.89 Abstract | Full Text TET2 is essential for survival and hematopoietic stem cell homeostasis K Shide, T Kameda, H Shimoda, T Yamaji, H Abe, A Kamiunten, M Sekine, T Hidaka, K Katayose, Y Kubuki, S Yamamoto, T Miike, H Iwakiri, S Hasuike, K Nagata, K Marutsuka, A Iwama, T Matsuda, A Kitanaka and K Shimoda Leukemia 2012 26: 2216-2223; advance online publication, April 3, 2012; 10.1038/leu.2012.94 Abstract | Full Text B-cell regulator of immunoglobulin heavy-chain transcription (Bright)/ARID3a is a direct target of the oncomir microRNA-125b in progenitor B-cells M P Puissegur, R Eichner, C Quelen, E Coyaud, B Mari, K Lebrigand, C Broccardo, F Nguyen-Khac, M Bousquet and P Brousset Leukemia 2012 26: 2224-2232; advance online publication, April 3, 2012; 10.1038/leu.2012.95 Abstract | Full Text Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors E Weisberg, Q Liu, Erik Nelson, A L Kung, A L Christie, R Bronson, M Sattler, T Sanda, Z Zhao, W Hur, C Mitsiades, R Smith, J F Daley, R Stone, I Galinsky, J D Griffin and N Gray Leukemia 2012 26: 2233-2244; advance online publication, April 3, 2012; 10.1038/leu.2012.96 Abstract | Full Text Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia C Palmi, E Vendramini, D Silvestri, G Longinotti, D Frison, G Cario, C Shochat, M Stanulla, V Rossi, A M Di Meglio, T Villa, E Giarin, G Fazio, A Leszl, M Schrappe, G Basso, A Biondi, S Izraeli, V Conter, M G Valsecchi, G Cazzaniga and G te Kronnie Leukemia 2012 26: 2245-2253; advance online publication, April 9, 2012; 10.1038/leu.2012.101 Abstract | Full Text CHRONIC MYELOPROLIFERATIVE NEOPLASIAS First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia D Rea, G Etienne, F Nicolini, P Cony-Makhoul, H Johnson-Ansah, L Legros, F Huguet, M Tulliez, M Gardembas, K Bouabdallah, P Rousselot, J-M Cayuela, F Guilhot and F-X Mahon Leukemia 2012 26: 2254-2259; advance online publication, March 30, 2012; 10.1038/leu.2012.92 Abstract | Full Text CHRONIC LYMPHOCYTIC LEUKEMIA N-(4-hydroxyphenyl)retinamide promotes apoptosis of resting and proliferating B-cell chronic lymphocytic leukemia cells and potentiates fludarabine and ABT-737 cytotoxicity S Bruno, F Ghiotto, C Tenca, A N Mazzarello, M Bono, P Luzzi, S Casciaro, A Recchia, A DeCensi, F Morabito and F Fais Leukemia 2012 26: 2260-2268; advance online publication, April 5, 2012; 10.1038/leu.2012.98 Abstract | Full Text LYMPHOMA Mast cells promote the growth of Hodgkin's lymphoma cell tumor by modifying the tumor microenvironment that can be perturbed by bortezomib H Mizuno, T Nakayama, Y Miyata, S Saito, S Nishiwaki, N Nakao, K Takeshita and T Naoe Leukemia 2012 26: 2269-2276; advance online publication, March 20, 2012; 10.1038/leu.2012.81 Abstract | Full Text E2F4 plays a key role in Burkitt lymphoma tumorigenesis I Molina-Privado, R Jiménez-P, S Montes-Moreno, Y Chiodo, M Rodríguez-Martínez, L Sánchez-Verde, T Iglesias, M A Piris and M R Campanero Leukemia 2012 26: 2277-2285; advance online publication, April 5, 2012; 10.1038/leu.2012.99 Abstract | Full Text MYELOMA Increased expression of extracellular matrix metalloproteinase inducer (CD147) in multiple myeloma: role in regulation of myeloma cell proliferation B K Arendt, D K Walters, X Wu, R C Tschumper, P M Huddleston, K J Henderson, A Dispenzieri and D F Jelinek Leukemia 2012 26: 2286-2296; advance online publication, March 30, 2012; 10.1038/leu.2012.91 Abstract | Full Text Letters to the Editor Top Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML S Ettou, E Audureau, C Humbrecht, B Benet, H Jammes, T Clozel, V Bardet, C Lacombe, F Dreyfus, P Mayeux, E Solary and M Fontenay Leukemia 2012 26: 2297-2299; advance online publication, June 5, 2012; 10.1038/leu.2012.152 Full Text Impact of bivaluridin and Genous stent in patients with acute myeloid leukemia undergoing emergency percutaneous coronary angioplasty for acute coronary syndrome G Galasso, T Niglio, S De Luca, C De Biase, V Parisi and F Piscione Leukemia 2012 26: 2300-2301; advance online publication, April 2, 2012; 10.1038/leu.2012.93 Full Text Corrigenda Top Generation and characterization of a novel hematopoietic progenitor cell line with DC differentiation potential C Rathinam, M Sauer, A Ghosh, C Rudolph, A Hegazy, B Schlegelberger, K Welte and C Klein Leukemia 2012 26: 2302; 10.1038/leu.2012.132 Abstract | Full Text Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up R A Larson, A Hochhaus, T P Hughes, R E Clark, G Etienne, D-W Kim, I W Flinn, M Kurokawa, B Moiraghi, R Yu, R E Blakesley, N J Gallagher, G Saglio and H M Kantarjian Leukemia 2012 26: 2302; 10.1038/leu.2012.175 Full Text Advertisement Ensure your access If you are unable to access the articles in this Table of Contents e-alert, your library may not subscribe to this journal. Our online recommendation form is a simple way to make your librarian aware that this journal is valuable to your research. Recommend now.   Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Leukemia. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2012 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.